// App-Quantinova.ai

P11.06 : Could LARP1 be a driving force in ovarian cancer transformation?

Researchers

Presenter

  • A. Coosemans

Principal Investigators

  • T. Baert

  • G. Verbist

  • A. Van Rompuy

  • D. Timmerman

  • I. Vergote

  • S. Blagden

Medical Centers

  • Gynecology and Obstetrics, UZ Leuven, Leuven, Belgium

  • Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, KU Leuven, Leuven, Belgium

  • Department of Development and Regeneration, Laboratory of Organ Systems, KU Leuven, Leuven, Belgium

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Department of Oncology, Laboratory of Gynecologic Oncology, KU Leuven, Leuven, Belgium

  • Department of Oncology, Old Road Campus Research Building, University of Oxford, Oxford, United Kingdom

Locations

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • BRCA mutation

  • Carbohydrate antigen 125

Drug/Treatment

  • STIC

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved